Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Castellaneta

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The New England Journal of Medicine|December 8, 2021
Inadequate SupportMarco Castellaneta
The New England Journal of Medicine|August 10, 2012
More on chronic cyclic non-nephrogenic magnesium depletion without lossesMarco Castellaneta, Cristoforo Castello
Archives of Dermatological Research|January 6, 2021
Follow-up of skin lesions during COVID-19: a description of a DRESS caseAlexandra Maria Giovanna Brunasso, Marco Castellaneta, Emanuele Pontali, et al.
International Journal of Dermatology|February 4, 2005
Coexisting pemphigus vulgaris and pemphigus foliaceus in the same patientClaudio Feliciani, Angela Motta, Marco Castellaneta, et al.
Recenti Progressi in Medicina|May 21, 2008
[The utility of assaying the N-terminal of brain natriuretic peptide precursor (NT pro-BNP) to predict the clinical outcome in patients with supraventricular tachyarrhythmias observed and treated in the emergency room]Antonio Magioncalda, Marina Sartini, Chiara Costaguta, et al.
Thrombosis Research|June 25, 2017
Pulmonary embolism prognostic factors and length of hospital stay: A cohort studyMarco Paolo Donadini, Francesco Dentali, Marco Castellaneta, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2020
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung diseaseEmanuele Pontali, Stefano Volpi, Giancarlo Antonucci, et al.
The Journal of Allergy and Clinical Immunology|February 8, 2021
Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumoniaEmanuele Pontali, Stefano Volpi, Alessio Signori, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The New England Journal of Medicine|December 8, 2021
Inadequate SupportMarco Castellaneta
The New England Journal of Medicine|August 10, 2012
More on chronic cyclic non-nephrogenic magnesium depletion without lossesMarco Castellaneta, Cristoforo Castello
Archives of Dermatological Research|January 6, 2021
Follow-up of skin lesions during COVID-19: a description of a DRESS caseAlexandra Maria Giovanna Brunasso, Marco Castellaneta, Emanuele Pontali, et al.
International Journal of Dermatology|February 4, 2005
Coexisting pemphigus vulgaris and pemphigus foliaceus in the same patientClaudio Feliciani, Angela Motta, Marco Castellaneta, et al.
Recenti Progressi in Medicina|May 21, 2008
[The utility of assaying the N-terminal of brain natriuretic peptide precursor (NT pro-BNP) to predict the clinical outcome in patients with supraventricular tachyarrhythmias observed and treated in the emergency room]Antonio Magioncalda, Marina Sartini, Chiara Costaguta, et al.
Thrombosis Research|June 25, 2017
Pulmonary embolism prognostic factors and length of hospital stay: A cohort studyMarco Paolo Donadini, Francesco Dentali, Marco Castellaneta, et al.
The Journal of Allergy and Clinical Immunology|May 22, 2020
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung diseaseEmanuele Pontali, Stefano Volpi, Giancarlo Antonucci, et al.
The Journal of Allergy and Clinical Immunology|February 8, 2021
Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumoniaEmanuele Pontali, Stefano Volpi, Alessio Signori, et al.
Pageof 1